Index Ventures is a venture capital firm established in 1996, with offices in London, San Francisco, and Geneva. The firm specializes in investing in high technology and life sciences, focusing on early-stage companies across various sectors including artificial intelligence, machine learning, fintech, healthcare, and entertainment. Index Ventures partners with innovative entrepreneurs who aim to transform their industries and has supported the growth of notable companies such as Adyen, Deliveroo, Dropbox, Farfetch, King, Slack, and Supercell. The firm's investment strategy typically involves allocating between $2 million to $20 million to promising ventures, primarily in Europe and the United States.
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Schlieren, Switzerland, focused on developing innovative therapies for serious diseases. The company is advancing a new class of small protein therapeutics known as DARPin, exemplified by its lead candidate Abicipar, which is undergoing Phase III clinical trials for wet age-related macular degeneration and diabetic macular edema. Other candidates in development include MP0250, aimed at enhancing standard treatments for multiple myeloma, and MP0274, currently in Phase I trials for HER2-positive solid tumors. Additionally, MP0310 is being evaluated in Phase I trials for immuno-oncology applications, while MPO317 and Peptide-MHC are designed to activate immune responses within tumors. Molecular Partners collaborates with notable partners, including Allergan and Amgen, and is engaged in a program to develop anti-COVID-19 therapeutics in partnership with AGC Biologics. Founded in 2004, the company aims to significantly improve disease management through its cutting-edge therapeutic approaches.
GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.
be2 S.à.r.l. is an online matchmaking service founded in 2004, initially launching its platform in Germany. It specializes in connecting individuals seeking long-term relationships, utilizing a scientific personality test to match users effectively. With a focus on international expansion, be2 operates in 37 countries across six continents, making it one of the largest and fastest-growing online matchmaking services in Europe. The company is headquartered in Luxembourg and also maintains an office in Zurich, employing a diverse team of 170 professionals from 43 nationalities. The management team brings extensive experience from various sectors of the online industry and has a proven track record in scaling startups into profitable enterprises.
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Schlieren, Switzerland, focused on developing innovative therapies for serious diseases. The company is advancing a new class of small protein therapeutics known as DARPin, exemplified by its lead candidate Abicipar, which is undergoing Phase III clinical trials for wet age-related macular degeneration and diabetic macular edema. Other candidates in development include MP0250, aimed at enhancing standard treatments for multiple myeloma, and MP0274, currently in Phase I trials for HER2-positive solid tumors. Additionally, MP0310 is being evaluated in Phase I trials for immuno-oncology applications, while MPO317 and Peptide-MHC are designed to activate immune responses within tumors. Molecular Partners collaborates with notable partners, including Allergan and Amgen, and is engaged in a program to develop anti-COVID-19 therapeutics in partnership with AGC Biologics. Founded in 2004, the company aims to significantly improve disease management through its cutting-edge therapeutic approaches.
GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.
GlycoVaxyn AG, a vaccine biopharmaceutical company, develops and manufactures biological conjugation vaccines against bacterial infections utilizing recombinant DNA technology. It develops and produces immunogenic glycoprotein conjugates vaccines for a range of bacterial diseases, such as pneumococcal and nosocomial infections. The company was incorporated in 2004 and is based in Schlieren, Switzerland. As of February 11, 2015, GlycoVaxyn AG operates as a subsidiary of GlaxoSmithKline plc.